Matrix metalloproteinases cleave the beta2-adrenergic receptor in spontaneously hypertensive rats.
We recently observed the enhanced serine and matrix metalloproteinase (MMP) activity in the spontaneously hypertensive rat (SHR) compared with its normotensive Wistar-Kyoto (WKY) rat and the cleavage of membrane receptors in the SHR by MMPs. We demonstrate in vivo that MMP-7 and MMP-9 injection leads to a vasoconstrictor response in microvessels of rats that is blocked by a specific MMP inhibitor (GM-6001, 1 microM). Multiple pathways may be responsible. Since the beta(2)-adrenergic receptor (beta(2)-AR) is susceptible to the action of endogenous MMPs, we hypothesize that MMPs in the plasma of SHRs are able to cleave the extracellular domain of the beta(2)-AR. SHR arterioles respond in an attenuated fashion to beta(2)-AR agonists and antagonists. Aorta and heart muscle of control Wistar rats were exposed for 24 h (37 degrees C) to fresh plasma of male Wistar and WKY rats and SHRs with and without doxycycline (30 microM) and EDTA (10 mM) to reduce MMP activity. The density of extracellular and intracellular domains of beta(2)-AR was determined by immunohistochemistry. The density of the extracellular domain of beta(2)-AR is reduced in aortic endothelial cells and cardiac microvessels of SHRs compared with that of WKY or Wistar rats. Treatment of the aorta and the heart of control Wistar rats with plasma from SHRs, but not from WKY rats, reduced the number of extracellular domains, but not intracellular domains, of beta(2)-AR in aortic endothelial cells and cardiac microvessels. MMP inhibitors (EDTA and doxycycline) prevented the cleavage of the extracellular domain. Thus MMPs may contribute to the reduced density of the extracellular domain of beta(2)-AR in blood vessels and to the increased arteriolar tone of SHRs compared with normotensive rats.
Rodrigues
Stephen F
SF
Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Tran
Edward D
ED
Fortes
Zuleica B
ZB
Schmid-Schönbein
Geert W
GW
D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D001011:Aorta / Q000201:enzymology; D001160:Arterioles / Q000201:enzymology / Q000503:physiopathology; D001794:Blood Pressure; D015153:Blotting, Western; D003331:Coronary Vessels / Q000201:enzymology; D004195:Disease Models, Animal; D006973:Hypertension / Q000201:enzymology* / Q000503:physiopathology; D007150:Immunohistochemistry; D007261:Infusions, Intra-Arterial; D008297:Male; D020783:Matrix Metalloproteinase 7 / Q000008:administration & dosage / Q000378:metabolism*; D020780:Matrix Metalloproteinase 9 / Q000008:administration & dosage / Q000378:metabolism*; D061965:Matrix Metalloproteinase Inhibitors; D011480:Protease Inhibitors / Q000494:pharmacology; D011499:Protein Processing, Post-Translational; D017434:Protein Structure, Tertiary; D051381:Rats; D011918:Rats, Inbred SHR; D011921:Rats, Inbred WKY; D017208:Rats, Wistar; D018343:Receptors, Adrenergic, beta-2 / Q000187:drug effects / Q000378:metabolism*; D013997:Time Factors; D014661:Vasoconstriction
D000318:Adrenergic beta-Agonists; D000319:Adrenergic beta-Antagonists; D061965:Matrix Metalloproteinase Inhibitors; D011480:Protease Inhibitors; D018343:Receptors, Adrenergic, beta-2; D020783:Matrix Metalloproteinase 7; D020780:Matrix Metalloproteinase 9
J Vasc Res. 2010;47(5):423-31
20145415
Br J Pharmacol. 2004 Oct;143(3):397-403
15351777
Br J Pharmacol. 2006 Sep;149(1):31-42
16880766
Adv Dent Res. 1998 Nov;12(2):12-26
9972117
Br J Pharmacol. 1997 Jul;121(5):1024-30
9222563
Metabolism. 2002 Mar;51(3):380-6
11887178
Circulation. 2001 May 8;103(18):2303-9
11342481
Int J Cardiol. 2001 Jul;79(2-3):277-86
11461752
Arch Physiol Biochem. 2008 Dec;114(5):340-8
19003589
Glia. 2005 Jun;50(4):329-39
15846802
Biochim Biophys Acta. 1984 Dec 20;802(3):390-8
6095918
J Vasc Res. 2001 May-Jun;38(3):228-36
11399895
FEBS Lett. 1986 Dec 1;209(1):9-12
2433154
Endocrine. 2009 Feb;35(1):1-10
18972226
Methods Mol Biol. 2001;151:121-48
11217296
Circ Res. 2000 Oct 13;87(8):670-6
11029402
Am J Physiol. 1997 May;272(5 Pt 2):H2173-9
9176283
Am J Pathol. 2004 May;164(5):1707-16
15111317
Hypertension. 1995 Oct;26(4):642-8
7558225
Clin Pharmacol Ther. 1990 Jul;48(1):87-95
2164458
Eur J Pharmacol. 1993 Dec 21;250(3):415-22
8112401
Hypertension. 1981 Sep-Oct;3(5):601-14
7298115
Hypertension. 1993 May;21(5):667-73
8387961
J Clin Invest. 2001 Mar;107(6):703-15
11254670
Circulation. 2002 Jul 16;106(3):349-55
12119252
Ann N Y Acad Sci. 2006 Nov;1085:117-32
17182928
J Pharm Pharmacol. 2002 Apr;54(4):515-22
11999129
Biochem Biophys Res Commun. 2006 Nov 3;349(4):1177-81
16979597
Hypertension. 1987 Feb;9(2):164-71
3818013
Mol Pharmacol. 2005 Apr;67(4):1128-36
15665254
Neurosurgery. 1994 Oct;35(4):711-9
7808615
Hypertension. 1997 Jan;29(1 Pt 2):519-24
9039153
Neurosci Lett. 2005 Mar 16;376(3):205-9
15721222
J Clin Invest. 1995 Jul;96(1):579-85
7615830
Circ Res. 2004 Jan 9;94(1):68-76
14656925
Hypertension. 2008 Aug;52(2):415-23
18606910
Curr Atheroscler Rep. 2004 Mar;6(2):112-20
15023295